There is no shortage of prognostication for the pharma industry in 2020. Every pundit with a pen and a microscope has a take. Top of everyone’s mind is how the coming presidential election will change the face of the industry, should we move closer to regulator and fiscal controls that might rein in the prices of healthcare and pharma over time.
Will this be the year that sets the tone for revolutionary changes in biopharma or will it be more of the same? We will let these industry experts weigh in so you can form your own opinion.